Bavarian Nordic Stock Plunge: What Caused The Drop?

Bavarian Nordic A/S is a Denmark-based biotechnology company that manufactures pharmaceutical preparations. The company's stock has been on a downward trajectory due to various factors, including short-seller attacks on its cancer vaccine and the strong bearish sentiment in the biotechnology industry. In particular, hedge fund Kerrisdale Capital's negative report on the company's cancer vaccine and subsequent short position impacted the stock price. Additionally, the economic turmoil caused by factors such as interest rate hikes and the Ukraine-Russia conflict have weighed heavily on the biotech industry, with Bavarian Nordic's shares falling 14.4% in the OTC market. However, there are reasons for optimism, including the company's focus on addressing high-risk tropical infections and its role in preventing global threats from pathogens.

Bearish sentiment weighs on the biotech industry

The biotech industry has been facing a challenging period due to strong bearish sentiment, and Bavarian Nordic A/S has not been immune to this trend. The company's stock price has been impacted by various market headwinds, resulting in a decline in performance relative to the broader market and the biotech sector.

Market Headwinds and Economic Turmoil

Aggressive interest rate hikes by central banks in Western countries, the negative consequences of the ongoing war in Ukraine, and skyrocketing energy bills have collectively contributed to a widespread negative sentiment in stock markets. The biotechnology subsector has been particularly vulnerable to these economic shocks, with stocks falling by an average of 10.9% year-to-date. Bavarian Nordic's shares have been significantly affected, losing 14.4% in the OTC market under the symbol BVNRY.

The Impact on Bavarian Nordic's Performance

Bavarian Nordic's stock has underperformed in the current market environment. While the market for BVNKF shares is relatively stagnant, the more active market for BVNRY shares has seen a notable decline. This suggests that Bavarian Nordic's stock has disappointed investors relative to its industry peers. The company's revenue and profitability have also taken a hit recently, with sales cooling off and higher research and development costs impacting the bottom line.

Opportunities for a Potential Rebound

Despite the bearish sentiment, there are reasons for optimism in the biotech industry and for Bavarian Nordic specifically. The company is at the forefront of developing vaccines for high-risk tropical infections and coronaviruses, including Monkeypox, Ebola, and COVID-19. The threat posed by these diseases continues to be a global concern, and Bavarian Nordic's expertise positions it well to address these challenges.

The Road to Recovery

Bavarian Nordic's role in combating global health threats cannot be understated. The company's portfolio includes vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola, among others. With the recent monkeypox outbreak, Bavarian Nordic has been in the spotlight, securing vaccine supply contracts with the US, Canada, Europe, and other countries. These deals have led to multiple upgrades in the company's revenue forecast for 2022. Additionally, the company is making significant R&D investments in its lead vaccine candidates for respiratory syncytial virus (RSV) and COVID-19.

In conclusion, while bearish sentiment has weighed on the biotech industry and Bavarian Nordic, there are catalysts for a potential rebound. The company's strategic focus on addressing global health threats and its ability to seize opportunities presented by emerging infectious diseases could drive a strong comeback in the future.

Sales and profitability decline

Bavarian Nordic's sales and profitability have declined in recent times. In the first six months of the current year, the company's portfolio of marketed and licensed vaccines generated total revenue of DKK 857 million (approximately $120.83 million), reflecting a 16.6% year-over-year decline in USD currency. This decline can be attributed to a decrease in sales of the company's Smallpox/Monkeypox vaccines, which accounted for 13.7% of total revenue, and Ebola vaccines, which accounted for 3.5% of total revenue. The company's net income also took a hit, with a net loss of DKK 509 million (approximately $71.76 million) in the first six months of the year, representing an over 80% deterioration from the previous year.

This decline in sales and profitability is partly due to the company's focus on research and development. Higher research and development costs, particularly in the company's two lead vaccine candidates for RSV and COVID-19, have contributed to an overall loss for the company. Despite this, the company's shareholders need not worry. Bavarian Nordic plays a crucial role in preventing global threats from pathogens, similar to its work during the coronavirus crisis.

The recent monkeypox outbreak has also impacted the company's performance. As one of the leading manufacturers of the monkeypox vaccine, Bavarian Nordic has seen increased demand and orders from various countries and organizations, including the European Health Emergency Preparedness and Response Authority (HERA) and the US government. These orders have provided a boost to the company's revenue forecast for 2022, now expected to be between 1,900 million Danish kroner (about $267 million) and 2,100 million Danish kroner (about $295 million).

However, the company's cancer vaccine has also faced criticism from short-seller Kerrisdale Capital, which argues that the valuation of the vaccine is based on misplaced faith in its likelihood of succeeding in Phase III trials. This negative sentiment has weighed on the company's stock price, causing it to slip by almost 7% in the two days after Kerrisdale released its report.

Short-sellers criticise cancer vaccine

Kerrisdale Capital, a New York-based hedge fund, has been highly critical of Bavarian Nordic's cancer vaccine, Prostvac, and has orchestrated a campaign against the company. In August 2015, Kerrisdale released a 52-page report arguing that the valuation of the Danish drugmaker was based on misplaced optimism about the vaccine's success in Phase III trials. Kerrisdale established a 2.7% short position on the company's shares, anticipating a decline in stock price if the vaccine failed.

Kerrisdale's critique centres on its interpretation of Prostvac's mid-phase trial data, which it believes appears impressive due to differences in the pre-study health of patients in the treatment and placebo groups. The hedge fund also examined data from a trial combining Prostvac with Bristol-Myers Squibb's Yervoy and concluded that "Prostvac itself accomplishes nothing."

In response to the short-seller's report, Bavarian Nordic's CEO, Paul Chaplin, defended the company, arguing that the placebo arm of the mid-phase trial accurately reflected the patient population at the time of the study. Chaplin also expressed continued belief in the power of combination treatments, including immunotherapies, to revolutionise cancer therapies.

The release of Kerrisdale's report caused Bavarian Nordic's share price to slip by almost 7% in two days. Additionally, the hedge fund has been lobbying fund managers at Danske Capital and Fundamental Invest to offload their shares. However, these fund managers have reportedly maintained their positions in Bavarian Nordic.

Kerrisdale's critique of Bavarian Nordic's cancer vaccine was validated in September 2017 when the vaccine failed its Phase 3 prostate cancer trial. This failure resulted in a significant drop in Bavarian Nordic's stock price, with shares falling more than 50%. The vaccine's inability to improve overall survival in patients with metastatic castration-resistant prostate cancer dashed hopes for the nearly $1 billion in milestones tied to the Bristol-Myers Squibb deal.

Negative economic factors impact stock markets

There are several negative economic factors that can impact stock markets and cause them to drop. Here are some key factors:

• Inflation and Deflation: High inflation can lead to decreased spending by companies, resulting in reduced revenue and higher costs for goods. This, in turn, causes a drop in the stock market. While deflation may seem beneficial, it is often perceived as a sign of a weak economy, leading to a decline in the stock market.
• Interest Rates: Higher interest rates established by central banks make borrowing more expensive for companies, impacting their profitability. As a result, companies may cut back on spending or lay off workers, leading to a drop in the stock market.
• Foreign Market Trends: Negative economic trends in foreign markets can affect the stock market in a given country. When foreign economies struggle, local companies may experience a decrease in revenue from overseas sales, causing a drop in the local stock market. Additionally, sharp drops or failures in foreign stock exchanges can create a ripple effect, leading to anticipation and uncertainty among local investors.
• Stability: Stock markets are sensitive to factors that threaten economic stability and future growth. This includes events such as terrorist attacks, spikes in oil prices, and political instability. These events can create uncertainty and cause stock markets to fall.
• Confidence and Expectations: The mood and expectations of investors play a crucial role in stock market movements. Bad economic news or negative developments can trigger investors to sell their shares, causing a decline in the market. Conversely, during a recession, if investors feel that the worst is over, the stock market can start to rally even before the economic fundamentals improve.
• Economic Growth: Lower economic growth or poor prospects for growth can impact the profitability of firms. Reduced demand for goods and services may lead to lower company dividends and share prices, affecting the stock market.
• War and Geopolitical Conflicts: Events like the war in Ukraine can have global economic repercussions, impacting energy, food, and commodity prices. This, in turn, can influence stock markets worldwide.

These negative economic factors can influence investor sentiment and impact stock markets. It is important for investors to be aware of these factors and their potential impact when making investment decisions.

High R&D costs and investments

Bavarian Nordic's stock has been affected by high research and development (R&D) costs and investments. The company has been making significant R&D investments in its two lead vaccine candidates – shots for respiratory syncytial virus (RSV) and COVID-19. These investments have contributed to the company's overall financial losses, despite increases in revenue.

In the first six months of the current year, Bavarian Nordic experienced a net loss of DKK 509 million, approximately $71.76 million, reflecting an 80% deterioration from the previous year. This loss can be attributed, in part, to the increased R&D expenditures associated with their vaccine development efforts.

The company's R&D investments are focused on advancing its vaccine pipeline, which includes a COVID-19 vaccine candidate, ABNCoV2, and a tumor antibody-boosted therapeutic vaccine, TAEK-VAC. ABNCoV2 is currently in Phase 3 clinical trials, demonstrating its potential as a booster vaccine against various COVID-19 mutations. TAEK-VAC is being investigated in an open-label Phase 1/2 study for patients with breast and lung cancer.

While these R&D investments have contributed to short-term losses, they also demonstrate Bavarian Nordic's commitment to innovation and addressing global health threats. The company's focus on high-risk tropical infections and coronaviruses positions it well for future opportunities, particularly in light of ongoing challenges posed by infectious diseases such as Monkeypox, Ebola, and COVID-19.

Despite the impact of high R&D costs on Bavarian Nordic's stock performance, the company's financial condition remains robust. As of June 30, 2022, Bavarian Nordic reported nearly $459 million in cash and short-term securities, providing a solid foundation for continued investment in vaccine development and future growth opportunities.

Frequently asked questions